Data highlights the potential of the pneumococcal vaccination against leading vaccine-preventable cause of childhood death
Health outcomes analysis predicts health and eEconomic benefits of routine pneumococcal vaccine use in Asian countries
Jakarta - /Medianet International-AsiaNet/ - Data from three studies conducted in Asia and presented last week indicate that routine childhood vaccination with a pneumococcal vaccine could help prevent a considerable proportion of this disease in vaccinated children, as well as unvaccinated adults.
The data also suggested that the vaccine is a highly cost-effective public health intervention, based on World Health Organization (WHO) criteria. The data were presented at the 6th International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD) in Reykjavik, Iceland.
"While there is a compelling body of evidence demonstrating the public health and economic impact of routine childhood vaccination in a number of countries, we now have data from Asia that convincingly support these benefits regionally," says Kenneth K.C. Lee, Ph.D., professor and associate director of External Affairs, School of Pharmacy, Faculty of Medicine, Chinese University of Hong Kong, China.
"By routinely vaccinating our children against pneumococcal disease, we have the ability to help protect the broader community unvaccinated children, parents and grandparents and, with evidence that routine vaccination represents a sound economic investment, there is no reason to delay action to help save lives now."
Specifically, data from Hong Kong and Singapore project that routine use of the pneumococcal vaccine over a 10-year period could prevent an estimated 524 cases and 290 cases of invasive pneumococcal disease (IPD), respectively, among the birth cohort.[1],[2]
In Hong Kong, these averted cases, when combined with more than 2,500 projected averted cases of otitis media, represent a HK$35 million (US$4.5 million) reduction in direct medical costs.[1] In addition, the data suggest that routine use of the vaccine in young children could help prevent approximately twice as many IPD cases in unvaccinated adults (919 cases in Hong Kong and 653 cases in Singapore), a phenomenon known as indirect effect or "herd" immunity.[1],[2]
Importantly, both studies conclude that routine use of vaccination can help substantially reduce the economic burden on health care systems.[1],[2] Other data presented at ISPPD confirm that the pneumococcal disease burden is high across Asian countries, with the reported incidence of IPD among children younger than five years of age ranging from 30.9 cases per 100,000 in Japan to 276 cases per 100,000 in Bangladesh.[3]
Importantly, the data also highlight that the pneumococcal vaccine could help prevent between 57 per cent and 91 per cent of IPD cases in children younger than two years of age in Asia.[3]
Study Notes
The Hong Kong study utilized an economic model to simulate the expected health outcomes resulting from routine pneumococcal vaccination of a birth cohort of 57,100 children over a 10-year horizon.[1] Local direct costs associated with the treatment of pneumococcal disease were obtained from hospital case records and the Hong Kong Hospital Authority.[1]
Outpatient treatment costs were estimated following interviews with 30 local general practitioners from different regions.[1]
The reduction in adult IPD cases and associated cost avoidance due to "herd" protection was estimated in line with published rates.[1] The analysis found that, from a payer perspective, universal pneumococcal vaccination was estimated to have an incremental cost per life year gained of HK$44,644 (US$5,718).[1]
The Singapore study reviewed hospital records from pediatric patients admitted to the KK Women's and Children's Hospital from January 1997 to December 2005 to determine the number of hospitalizations due to pneumococcal disease and costs associated with patient treatment.[2]
These data were used to populate an economic model to simulate the impact of a universal vaccination program in Singapore.[2] From a payer perspective, the program was estimated to have an incremental cost per life year gained of SGD$9,449-SGD$27,240 (US$6,992-$20,157).[2]
The regional analysis reviewed pneumococcal disease data in Bangladesh, China, Hong Kong, Japan, Korea, New Zealand, Singapore, Sri Lanka and Vietnam, and estimated the potential impact of the 7-valent pneumococcal conjugate vaccine and the
investigational 10- and 13-valent vaccines.[3] Data were identified searching the OVID database (1997-2007) and country and World Health Organization (WHO) Web sites.[4] Serotype distribution varied by age, geography and pneumococcal disease type.[4]
The pneumococcal conjugate vaccine (PCV-7) is available in Indonesia in the private market since 2006 and listed as a
recommended schedule for infant and children under 5 years old by Indonesia Pediatric Society (IDAI).
REFERENCES:
[1] Lee K, Rinaldi F, Lee V, et al. Economic evaluation of universal infant vaccination with 7vPCV in Hong Kong. Abstract presented at the 6th International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD).
[2] Rinaldi F and Chong C. Predicted impact of a universal infant 7vPCV vaccination program in Singapore. Abstract presented at the 6th International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD).
[3] Garcia C, Center K and Herrera G. Burden of pneumococcal disease (PD) in the Asia-Pacific (AP) region: importance of inclusion of pneumococcal conjugate vaccine (PCV) into national immunization programs (NIPs). Abstract presented at the 6th International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD).
[4] World Health Organization. Pneumococcal conjugate vaccine for childhood immunization, March 2007- WHO position paper. Wkly Epidemiol Record 2007;12: 93-104.
Media Contact: Wendy Qin +62 2 8424 8522 +62 404 101 742
SOURCE: Wyeth
Health outcomes analysis predicts health and eEconomic benefits of routine pneumococcal vaccine use in Asian countries
Jakarta - /Medianet International-AsiaNet/ - Data from three studies conducted in Asia and presented last week indicate that routine childhood vaccination with a pneumococcal vaccine could help prevent a considerable proportion of this disease in vaccinated children, as well as unvaccinated adults.
The data also suggested that the vaccine is a highly cost-effective public health intervention, based on World Health Organization (WHO) criteria. The data were presented at the 6th International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD) in Reykjavik, Iceland.
"While there is a compelling body of evidence demonstrating the public health and economic impact of routine childhood vaccination in a number of countries, we now have data from Asia that convincingly support these benefits regionally," says Kenneth K.C. Lee, Ph.D., professor and associate director of External Affairs, School of Pharmacy, Faculty of Medicine, Chinese University of Hong Kong, China.
"By routinely vaccinating our children against pneumococcal disease, we have the ability to help protect the broader community unvaccinated children, parents and grandparents and, with evidence that routine vaccination represents a sound economic investment, there is no reason to delay action to help save lives now."
Specifically, data from Hong Kong and Singapore project that routine use of the pneumococcal vaccine over a 10-year period could prevent an estimated 524 cases and 290 cases of invasive pneumococcal disease (IPD), respectively, among the birth cohort.[1],[2]
In Hong Kong, these averted cases, when combined with more than 2,500 projected averted cases of otitis media, represent a HK$35 million (US$4.5 million) reduction in direct medical costs.[1] In addition, the data suggest that routine use of the vaccine in young children could help prevent approximately twice as many IPD cases in unvaccinated adults (919 cases in Hong Kong and 653 cases in Singapore), a phenomenon known as indirect effect or "herd" immunity.[1],[2]
Importantly, both studies conclude that routine use of vaccination can help substantially reduce the economic burden on health care systems.[1],[2] Other data presented at ISPPD confirm that the pneumococcal disease burden is high across Asian countries, with the reported incidence of IPD among children younger than five years of age ranging from 30.9 cases per 100,000 in Japan to 276 cases per 100,000 in Bangladesh.[3]
Importantly, the data also highlight that the pneumococcal vaccine could help prevent between 57 per cent and 91 per cent of IPD cases in children younger than two years of age in Asia.[3]
Study Notes
The Hong Kong study utilized an economic model to simulate the expected health outcomes resulting from routine pneumococcal vaccination of a birth cohort of 57,100 children over a 10-year horizon.[1] Local direct costs associated with the treatment of pneumococcal disease were obtained from hospital case records and the Hong Kong Hospital Authority.[1]
Outpatient treatment costs were estimated following interviews with 30 local general practitioners from different regions.[1]
The reduction in adult IPD cases and associated cost avoidance due to "herd" protection was estimated in line with published rates.[1] The analysis found that, from a payer perspective, universal pneumococcal vaccination was estimated to have an incremental cost per life year gained of HK$44,644 (US$5,718).[1]
The Singapore study reviewed hospital records from pediatric patients admitted to the KK Women's and Children's Hospital from January 1997 to December 2005 to determine the number of hospitalizations due to pneumococcal disease and costs associated with patient treatment.[2]
These data were used to populate an economic model to simulate the impact of a universal vaccination program in Singapore.[2] From a payer perspective, the program was estimated to have an incremental cost per life year gained of SGD$9,449-SGD$27,240 (US$6,992-$20,157).[2]
The regional analysis reviewed pneumococcal disease data in Bangladesh, China, Hong Kong, Japan, Korea, New Zealand, Singapore, Sri Lanka and Vietnam, and estimated the potential impact of the 7-valent pneumococcal conjugate vaccine and the
investigational 10- and 13-valent vaccines.[3] Data were identified searching the OVID database (1997-2007) and country and World Health Organization (WHO) Web sites.[4] Serotype distribution varied by age, geography and pneumococcal disease type.[4]
The pneumococcal conjugate vaccine (PCV-7) is available in Indonesia in the private market since 2006 and listed as a
recommended schedule for infant and children under 5 years old by Indonesia Pediatric Society (IDAI).
REFERENCES:
[1] Lee K, Rinaldi F, Lee V, et al. Economic evaluation of universal infant vaccination with 7vPCV in Hong Kong. Abstract presented at the 6th International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD).
[2] Rinaldi F and Chong C. Predicted impact of a universal infant 7vPCV vaccination program in Singapore. Abstract presented at the 6th International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD).
[3] Garcia C, Center K and Herrera G. Burden of pneumococcal disease (PD) in the Asia-Pacific (AP) region: importance of inclusion of pneumococcal conjugate vaccine (PCV) into national immunization programs (NIPs). Abstract presented at the 6th International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD).
[4] World Health Organization. Pneumococcal conjugate vaccine for childhood immunization, March 2007- WHO position paper. Wkly Epidemiol Record 2007;12: 93-104.
Media Contact: Wendy Qin +62 2 8424 8522 +62 404 101 742
SOURCE: Wyeth
No comments:
Post a Comment